SEPTEMBER 21, 2016
Jupiter, FL: Cytonics Corporation, a biotechnology company focused on the development of biologic therapies for musculoskeletal diseases, today announced that the Intellectual Property Office of the UK granted patent GB2522561B covering the APIC-PRP system for concentrating Alpha-2-Macroglobulin (A2M)from human blood. Cytonics’ APIC-PRP system selectively enriches A2M while removing inflammatory mediators (such as cytokines) from the blood plasma, providing an A2M-rich preparation which is injected into damaged joints. This proprietary technology is being developed to treat cartilage degeneration in diseases such as osteoarthritis.
Alpha-2-Macroglobulin (A2M) is an abundant, endogenous blood protein that inhibits all classes of serine proteases and metalloproteases, thereby decreasing protein degradation involved in osteoarthritis and attenuating joint pain. Cytonics’ recombinant Alpha-2-Macroglobulin variant, Cyt-108, is a synthesized protein that contains a series of mutations within the bait region of the protein structure. The mutated bait region was designed to increase the potency of the A2M molecule, allowing small doses to have large therapeutic effects.
“All of the science intimates at the potential for Alpha-2-Macroglobulin to become a standard treatment for musculoskeletal diseases. Up until this point, A2M has not been explored in a clinical setting. Our APIC-PRP therapy has demonstrated outstanding success in clinical practice, making it the first of its kind.”Gaetano Scuderi, MD
Founder and CEO of Cytonics
Cytonics, founded in 2006, is a private research and development company focusing on molecular diagnostic and therapeutic products for chronic musculoskeletal diseases. The company developed the FACT diagnostic test which helps identify the source of back and joint pain and assists physicians in determining the most appropriate treatment. Cleared in January of 2014, Cytonics developed the Autologous Platelet-Integrated Concentrate (APIC) System as a
concentrate and other forms of A2M therapeutics, including optimized recombinant forms. The company is currently pursuing pre-clinical studies for their lead recombinant A2M candidate, Cyt-108.
658 W. Indiantown Rd. Suite 214
Jupiter, FL 33458